1832 Asset Management
ACAD icon

1832 Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

1832 Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-53,300
Closed -$2.22M – 642
2020
Q1 		$2.22M Buy
53,300
+15,100
+40% +$622K 0.01% 395
2019
Q4 		$1.66M Buy
+38,200
New +$1.66M 0.01% 395

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

1832 Asset Management's ACAD Position: Q2 2020 in Review

1832 Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 53,300 shares — an estimated $2.22M sold.

1832 Asset Management first reported a position in ACAD in Q4 2019 and held it in 2 quarters. The position peaked at $2.22M in Q1 2020. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • 1832 Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • 1832 Asset Management sold 53,300 Acadia Pharmaceuticals shares in Q2 2020, an estimated $2.22M.
  • 1832 Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • 1832 Asset Management's Acadia Pharmaceuticals position peaked at $2.22M in Q1 2020.
  • 298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on 1832 Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.